Laboratory Activ Participant To Clinical Trials [Tryb ZgodnośCi]

1,990 views

Published on

0 Comments
2 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
1,990
On SlideShare
0
From Embeds
0
Number of Embeds
5
Actions
Shares
0
Downloads
52
Comments
0
Likes
2
Embeds 0
No embeds

No notes for slide

Laboratory Activ Participant To Clinical Trials [Tryb ZgodnośCi]

  1. 1. CLINIC LABORATORY - ACTIV PARTICIPANT IN CLINICAL TRIALS - Cristina Florescu Moraid MD, MSc. EurClinChem
  2. 2. AGENDA Purpose of the presentation Clinical trial: definition, classification, major players Role of clinical laboratory Rules to follow if participating in CT Audits of clinical laboratory Trends in clinical research industry Synevo Central Lab experience Conclusions
  3. 3. PURPOSE OF THE PRESENTATION Why to talk about clinical trials? Conducting CT represents an average of 37% of the total cost to bring a new medicine to market R&D spending reached $140 billion by 2009
  4. 4. PURPOSE OF THE PRESENTATION Laboratory vs R & D Laboratory testing represents a critical step in supporting the evaluation of a new product Laboratory industry generated in 2006 $1.8 billion dollars and reached $ 2.9 billion end of 2009
  5. 5. AGENDA - cont’ Purpose of the presentation Clinical trial: definition, classification, major players Role of clinical laboratory Rules to follow if participating in CT Audits of clinical laboratory Trends in clinical research industry Synevo Central Lab experience Conclusions
  6. 6. CLINICAL TRIALS - definition Clinical Trials are studies performed with human subjects to test new drugs or combinations, new approaches to surgery or radiotherapy or procedures to improve the diagnosis of disease and the quality of life of the patient
  7. 7. What is a clinical trial? (directive 2001/20/EC, art.2) Any investigation in human subjects intended to discover or verify the clinical, pharmacological and/or other pharmacodynamic effects of an investigational product(s) and/or to identify any adverse reactions to an investigational product(s), and/or to study absorption, distribution, metabolism, and excretion of an investigational product(s) with the object of ascertaining its safety and/or efficacy.
  8. 8. What are the different types of clinical trials? Treatment trials: test experimental treatments, new combinations of drugs or new approaches to surgery or radiation therapy Prevention trials: look for better ways to prevent disease in people who have never had the disease or to prevent a disease from returning; e.g.: medicines, vaccines, vitamins, minerals Diagnostic trials : for finding better tests or procedures for diagnosis a particular disease or condition Screening trials : test the best way to detect certain diseases or health conditions Quality of life trials : explore ways to improve comfort and the quality of life for individuals with chronic illness Genetic studies, behavioral studies, epidemiology or population based studies: as parts of cancer clinical trials
  9. 9. WHAT ARE THE PHASES OF DRUG DEVELOPMENT? YEARS PHASE 15 14 Drug registration Post registration IV 13 Introduction to the market observations 1 12 11 2 III 10 Drug testing CLINICAL RESEARCH 9 2-5 II 8 7 5-10 I 6 PRECLINICAL STUDIES Potential drug testing 10 - 20 5 4 3 Synthesis Basic research 3000 - 10000 2 Testing 1 Searching NUMBER OF TESTED MOLECULES •Early phase (Phases I and II) Safety and tolerance Clinical pharmacology Efficacy endpoints Small sample size •Late phase (Phase III or pivotal study) Commercial scale and formulation Large sample size Greater patient variability •Post registration phase (IV) •Marketing support and line-extension
  10. 10. Phases of Clinical Development Phase I : Usually studies in health volunteers (“first in men” (clinical pharmacology=pharmacokinetics & pharmacodynamic) Number of subjects: 12, 24 or 36 Exceptions: studies in cancer research and other indications with chemotherapy(e.g. multiple sclerosis). In this cases pharmacokinetics will be investigated in patients
  11. 11. Phases of Clinical Development Phase II : First studies in patients of interesting indications (pilot studies” in efficacy, proof of concept, dose findings) Number of subjects: at least 8 up to 24 or hundreds Phase III : larger studies in patients of interesting indications (from a statistical point of view: ”confirmatory studies” in efficacy, tolerability) Purpose for registration, evidence for efficacy Number of subjects: from 50-60 up to thousands
  12. 12. Phases of Clinical Development Phase IV / post marketing studies: same as for phase III; larger studies in patients of interesting indications, but after marketing authorization Purpose: further evidence, other treatments schemes, marketing effects, drug’s risks Number of subjects: according to statistical considerations, from 100 up to 10000 or more The drug is on the market! “Add on therapy”
  13. 13. WHO PERFORMS CLINICAL RESEARCH? Sponsors Pharmaceutical Companies Contract Research Organisation (CRO) Investigators Site Management Organisation (SMO) Physicians (investigators) Laboratory Sponsor CRO/SMO Laboratory Investigator
  14. 14. Clinical trials - it’s all about data Subject Diary CRF DCF Investigator Monitor Statistician Sample CRF DCF NDA Clinical Lab Data Results Regulatory Authority Central Data Manager Clinician Laboratory
  15. 15. AGENDA - cont’ Purpose of the presentation Clinical trial: definition, classification, major players Role of clinical laboratory Rules to follow if participating in CT Audits of clinical laboratory Trends in clinical research industry Synevo Central Lab Experience Conclusions
  16. 16. Roles and Responsibilities SPONSOR Pharmaceutical Company Drug development Main sponsor contracts out different CROs and/or Investigators CRO Subcontractor to different pharmaceutical companies Responsible for clinical trials - Sponsor representative INVESTIGATOR SMO Clinical site coordinator - Investigator representative Physician (investigator) Subcontractor to SMO Crucial part of clinical research Direct contact with patient
  17. 17. INVESTIGATOR
  18. 18. INVESTIGATOR Must be qualified (MDs) Must have adequate resources (suitable subjects) Must be compliant with the protocol Is responsible for drug storage and drug accountability Should provide the subject ample time and opportunity to inquire about details The written consent should be signed before any trial will start Should promptly provide written reports to the sponsor, IEC,etc,on any changes significantly affecting the conduct of the trial Must stay in close contact with laboratory and monitor Should report immediately all SAE s to the sponsor (SAE = death, life treating, teratogen effects, cancer, prolongation of hospitalization)
  19. 19. SPONSOR Is responsible for implementing and maintaining QA (quality assurance) and QC (quality control) systems with written SOPs to ensure that trials are conducted and data are generated, recorded and reported in compliance with the protocol, GCP and applicable regulatory requirements A sponsor may transfer any or all of the sponsor’s trial-related duties and functions to a CRO (contract research organization) Should utilize qualified individuals (biostatisticians, pharmacologists, physicians) throughout all stages of the trial, to supervise the conduct of the trial, to verify the data, to prepare the trials records, etc Is responsible for selecting the investigators / institution/laboratory Ensure that the systems are designated to permit data changes in such a way that the data changes are documented and there is no deletion of entered data
  20. 20. MONITOR/CRO Should verify that the rights and well-being of the subjects are protected and the reported trial data are accurate, complete and verifiable from source documents Is responsible for verifying that the investigator has adequate qualifications and resources Verifying that the investigator follows the approved protocol and all approved amendment (s) Verifying the laboratory’s accreditation and GCP compliance Verifying that written informed consent was obtained before each subject’s participation in the trial
  21. 21. WHERE LAB CAN HELP? Sponsor level: study protocol design (e. g suitable blood volume, selecting the proper analyzing method and equipment, choosing proper test panels in relation to the study pathology, study specific data base, study specific report formats, method development according to study goal, etc) Monitor level: professional expertise for pre- and post-analytical phases of testing (e.g. sample preparation, sampling kits assembling, logistics tasks such as dry ice and courier providers, etc.) Investigator level: on site training for proper patient sampling, laboratory data interpretation referred to the study pathology, etc.
  22. 22. LABORATORY ROLE Laboratory can play within a clinical study the role of: Local lab: only testing Regional Lab: testing and logistics Central Lab: testing, logistics, data and project management
  23. 23. AGENDA - cont’ Purpose of the presentation Clinical trial: definition, classification, major players Role of clinical laboratory Rules to follow if participating in CT Audits of clinical laboratory Trends in clinical research industry Synevo Central Lab experience Conclusions
  24. 24. Important definitions: GCP=good clinical practice GLP=good laboratory practice GLP doesn’t apply to laboratory testing human samples Clinical means humans (GCP) Laboratory means others than humans (GLP) GLP doesn’t apply to clinical trials GCLP=good clinical laboratory practice GCLP applies exclusively to clinical trials
  25. 25. AGENDA - cont’ Purpose of the presentation Clinical trial: definition, classification, major players Role of clinical laboratory Rules to follow if participating in CT Audits of clinical laboratory Trends in clinical research industry Synevo Central Lab experience Conclusions
  26. 26. Audit-a MUST for participation to CT ICH-GCP (CPMP/ICH/135/95): Audit: ”A systematic and independent examination of trial related activities and documents to determine whether the evaluated trial related activities were conducted, and the data were are recorded, analyzed and accurately reported according to the protocol, sponsor’s standard operating procedures (SOPs), Good Clinical Practice (GCP) and the applicable regulatory requirement (s).” (Glossary, 1.6)
  27. 27. Audit-a MUST for participation to CT ICH-GCP (CPMP/ICH/135/95): 5.19.1 Audits should be performed “separate from routine monitoring or quality control functions”.
  28. 28. QC versus QA “Quality Control are the procedures in place to ensure that the process is in control (the big Q)” “Quality Assurance is an audit function verifying that all QC procedures are effective (the little q).” E.M.Sullivan, M.A. Gorko, R.C. Stellon & G. Chao (1997) Drug Information Journal
  29. 29. General Management System Audit Clinical Research QA CRO QC Planning of clinical studies Preparation of documents Identification of centres M Initiation of the study o Delivery of trial supplies n Data capture i Control of processes, data and documents, SDV t Collecting material o and returned drugs r 2nd Review of data (CRF) Data Management, statistical evaluation and analysis Final Report (E3)
  30. 30. General Management Sponsor QA CRO External System Audits Laboratory (Clin. or Bioanalyt.) Data Management/ Biostatistics etc.
  31. 31. Guideline for Auditing Clinical Laboratories Audit covers: Overall management of the facility Quality management systems The handling, analysis and result reporting of samples reporting for samples processed Data management Computer systems (compliance with 21CFR Part 11) Archiving
  32. 32. Auditor at work: 9/24/2010 32
  33. 33. Clinical Laboratory Audit Checklist : 1.Safety Resources e.g. Is there a lab safety manual/ departamental safety manual? what is the evacuation policy? UV light policy? emergency management policy? 2. Laboratory Housekeeping e.g. Are walls and ceilings clean and well maintained? 3. General Safety Awareness e.g. Have all employees completed/reviewed the Laboratory Safety Evaluation Form within the last year? Have all employees who work with human blood/products been offered the hepatitis B vaccine? 4. Personal Protective Equipment (PPE) e.g. Do personnel decontaminate hands (i.e. handwashing) after removal of gloves? Is reusable clothing (i.e. lab coats) used for work with blood and blood products being collected in laundry bags that are either labelled or colour-coded as “biohazardous”? 5. Biological Safety e.g. Are surfaces on which work involving blood and blood products is performed routinely wiped down with an approved disinfectant at the end of the procedure or immediately following a spill? 6. Fire Safety e.g. Are employees familiar with the location of fire extinguishers and pull alarms? Does the lab avoid placing electrical devices near water sources?
  34. 34. Clinical Laboratory Audit Checklist : 7. Chemical Safety e.g. Are the containers for all hazardous chemicals properly labelled with the chemical name, hazard type, and what to do if accidental contact occurs? 8. Quality Management System e.g. Are all relevant operations that are standardizable described in SOPs in writing? Describe, which operations are covered by SOPs. Is there evidence that all Individuals have access to the SOPs relevant to them and have they fully understand the meaning? Will internal audits be performed on a regular basis? If so, describe by whom and when 9. Specimen Handling e.g. Are there procedures for specimen transport? Is there sufficient information to allow unique identification of: the patient?/ the specimen? Are details relating to the patient and specimen available? date and time of collection? type of specimen? investigations requested? date and time of receipt? clinical information? 10. Examination Procedures & Equipment 11. Staff Training 12. Reporting Results
  35. 35. AGENDA - cont’ Purpose of the presentation Clinical trial: definition, classification, major players Role of clinical laboratory Rules to follow if participating in CT Audits of clinical laboratory Trends in clinical research industry Synevo Central Lab experience Conclusions
  36. 36. Trends in clinical research industry TALKING ABOUT THE PAST When a CT commenced and laboratory test data was returned, pharmaceutical companies would typically receive data with a 39% error rate Mislabeled test kits, incorrect tests, missing specimens caused data inaccuracies
  37. 37. DURING THE TIME… Analysis of CT data required months of work, with data having to be “cleaned” first before it could be analyzed Data was gathered from multiple local laboratories, that used different methodologies, reference ranges and SOPs
  38. 38. CENTRAL LABORATORY IDEA In order to deliver to study sponsors faster access to higher quality of data, faster receipt, analysis and a significantly reduced rate of error, the idea of CENTRAL LABORATORY has been conceived
  39. 39. CENTRAL LABORATORY IDEA-cont’ Through the establishment of relationship with global logistics couriers, standardization in the production of sampling kits and the development of a single database, the CL industry has been able to deliver combinable data to CT sponsors
  40. 40. CENTRAL LABORATORY versus LOCAL LABS Investigators and sponsors expect lab results to be reported immediately after the central lab receives the samples Result reporting within 12-24h may be easy to achieve for routine testing methods For more complex and specialized methods, the frequency of running a specific assay in laboratory directly depends on the number of samples received
  41. 41. CENTRAL LABORATORY versus LOCAL LABS- cont’ The high cost of instrumentation (up to $250,000) and reagents($1000 for a kit to test approximately 40 samples) in addition to qualified technicians, explain why laboratories need a minimum batch size to offer competitive lab fees to sponsors
  42. 42. CENTRAL LABORATORY versus LOCAL LABS- cont’ A small laboratory processing 50 or 100 samples a day may only receive 5-10 samples for a specific immunology method This “imaginary” lab would only be able to run the immunology assay 2-3 times a month at a higher cost per unit A central lab with a capacity to process 5000 or more samples per day has the advantage of both offering competitive prices and reporting lab results with the shortest delays What to use then?
  43. 43. HOW TO ANSWER TO THIS DILEMMA? Smaller laboratories may be good for local studies where testing portfolio is not too demanding, but they will not have the volume to cope with test panels that are becoming more complex Central laboratories following the strategies mentioned previously may succeed in supporting global studies if they have an established worldwide infrastructure and a solid quality system in place
  44. 44. WHAT IS THE TREND IN THE PRESENT? Nowadays, CT are globalized, places that may sound exotic such as Eastern Europe, Asia-Pacific or Latin America, offer distinct advantages for sponsors: large pools of treatment-naïve patients, faster and less competitive enrollment, lower costs per patient On the other hand, the increased logistics costs reffered to may be higher than the laboratory costs Also, a considerable number of samples are not able to reach the analytical facility under adequate conditions to be properly analyzed The patient recall for sample drawing may take up to one week, sometimes more, and represents a delay in the study schedule and negatively affect patient adherence
  45. 45. HOW TO SOLVE THE DILEMMA? By using the Local Central Lab Model based on harmonization process Harmonized analytical platform Harmonized reference ranges Similar certification, accreditation and external QC programs Harmonized lab report formats Harmonized database
  46. 46. AGENDA - cont’ Purpose of the presentation Clinical trial: definition, classification, major players Role of clinical laboratory Rules to follow if participating in CT Audits of clinical laboratory Trends in clinical research industry Synevo Central Lab experience Conclusions
  47. 47. SYNEVO CENTRAL LAB(SCL) Leading provider of central laboratory services for clinical trials in Central and Eastern Europe (CEE). We are a part of MEDICOVER family (€200M revenues in 2009), the largest health service company in CEE. We are a shareholder in LabConnect, US- based central laboratory which operates across five continents. 24-Sep-10 47
  48. 48. OUR NUMBERS 14+ years of experience in clinical trials 30+ employees exclusively dedicated to clinical trials 50+ laboratories within the European network 200+ successfully completed projects 1500+ validated tests 24-Sep-10 48
  49. 49. Coverage | Europe Synevo Central Lab Operations Strategic partners 24-Sep-10 49
  50. 50. Coverage | Global 24-Sep-10 50
  51. 51. EXPERIENCE SCL Distribution acc. to Central vs. local phases services 9/24/2010 General presentation 51
  52. 52. Worldwide CTs distribution 1% 2% 2% 3% 4% 47% 12% 14% 15% Endocrino ORL Pediatrics Psychiatry Neurology Rheumato CV Diseases Pulmonary Dermato/Plastic surgery Nephrology Musculoskeletal Immunology Gastro Obstetrics Hemato Onchology
  53. 53. Experience SCL d 24-Sep-10 53
  54. 54. PRESENT SITUATION OF PROJECTS IN SCL Romania 31 53 8 Pipeline Start-up phase Ongoing TOTAL 92 PROJECTS
  55. 55. CONCLUSIONS None of existing treatments result in a cure of all patients, nor are they without side effects, and doctors continue looking for better ways to treat the disease Clinical laboratory plays a very important role in any clinical trial by offering reliable data for the patient’s diagnosis and the trial success Only by common effort of all involved partners in the research field, better ways to treat disease will be developed and the patients health status will be significantly improved Beside the other benefits reached by the participating into a clinical trial, none of us should ever forget that everything starts and ends with the patient!

×